Cleveland Clinic study reveals zinc and vitamin C are not effective treatments for COVID-19
Cleveland Clinic researchers have found that zinc or ascorbic acid (vitamin C) – or a combination of the two – do not significantly decrease the severity or duration of symptoms in COVID-19-positive patients, when compared to standard care, reported the clinic in a news release. The study was published today in JAMA Open Network.
Since the start of the COVID-19 pandemic there has been widespread speculation about the role of various vitamins and supplements to prevent or treat it, but there remains limited scientific evidence. Zinc is known to be important for immune function. It also has a role in antibody and white blood cell production and can fight infections. Vitamin C, an antioxidant, can help reduce damage to cells, and has shown to be immune boosting.
The COVIDAtoZ clinical trial enrolled 214 adult patients with a confirmed COVID-19 infection. Patients were randomized and either received 10 days of zinc gluconate (50 mg), vitamin C (8000 mg), both agents, or standard of care from April 2020 to October 2020. The study was stopped for futility, with no significant difference among the four groups. Specifically the endpoint of a 50 percent reduction in symptoms showed no significant difference between the usual care, vitamin C, zinc gluconate or the group receiving both vitamin C and zinc gluconate.
“When we began this trial, there was no research to support supplemental therapy for the prevention or treatment of patients with COVID-19,” said Milind Desai, M.D., MBA, director, clinical operations in Cleveland Clinic’s Heart Vascular & Thoracic Institute and co-principal investigator of the study. “As we watched the pandemic spread across the globe, infecting and killing millions, the medical community and consumers alike scrambled to try supplements that they believed could possibly prevent infection, or ease COVID-19 symptoms, but the research is just now catching up. While vitamin C and zinc proved ineffective as a treatment when clinically compared to standard care, the study of other therapeutics continues.”
The patients enrolled in this study were not hospitalized, but rather managed on an outpatient basis. “We know that not all patients with COVID-19 require hospital admission and compared to those being treated in a hospital setting, they are more likely to be seeking out supplements that could help them, so it was an important population to study,” said Suma Thomas, M.D., MBA, vice-chairman of strategic operations in Cleveland Clinic’s Heart Vascular & Thoracic Institute and co-principal investigator of the study.
A total of four safety events were observed during the trial, including three deaths, however the data safety monitoring board did not believe that any of the adverse events were caused by individual treatments that patients received as a part of the study.
